(2022) showed that short-term, high-dose recombinant human nerve growth factor (rhNGF) eye drop treatment was associated with trends toward improvement in certain structural and functional parameters; however, due to the small sample size and nonrandomized design, these outcomes did not reach statistical significance, and the therapeutic efficacy remains uncertain.
← all excerpts
Microglial regulation of synaptic plasticity in transsynaptic degeneration of glaucoma.
1
—
—